Next Earnings date is expected on
08/12/2022
Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $3 to $6, according to analysts polled by Capital IQ. (MT...
Leap Therapeutics (LPTX) and BeiGene, Ltd (BGNE) said Tuesday that they have initiated Part C of an ongoing study on Leap's treatment DKN-01 in combination...
Leap Therapeutics (LPTX) has an average rating of outperform and price targets ranging from $4 to $6, according to analysts polled by Capital IQ. (MT...
Leap Therapeutics (LPTX) said Monday that it has teamed up with Leica Biosystems to develop a companion diagnostic to detect Dickkopf-related protein 1....
| Address | 47 Thorndike Street Cambridge, Massachusetts 02141 |
| Phone | +1.617.714.0360 |
| Number of Employees | 25 |
| Recent SEC Filing | 07/12/2022 8-K |
| President, CEO, CFO, Secretary & Treasurer | Doug E. Onsi |
| Chief Operating Officer | Augustine J. Lawlor |
| Chief Medical Officer | Cynthia Sirard |
| Head-Research | Michael Haas |
| Price Open | $1.18 |
| Previous Close | $1.30 |
| 52 Week Range | $0.92 - 4.17 |
| Market Capitalization | $114.8 M |
| Shares Outstanding | 88.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/12/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.48 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -3,718.13% |
| Return on Equity | -47.38% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
